Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Antibody
260€ (50 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx213416
tested applications
ELISA, WB
Description
ACMSD Antibody is a Rabbit Polyclonal against ACMSD.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) |
| Host | Rabbit |
| Reactivity | Human, Mouse |
| Recommended Dilution | ELISA: 1/2000 - 1/5000, WB: 1/500 - 1/2000. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purification | Antigen Affinity Chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, WB |
| Buffer | PBS, pH 7.4, containing 0.05% NaN3 and 40% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q8TDX5 |
| Gene ID | 130013 |
| Alias | ACMSD |
| Background | Antibody anti-ACMSD |
| Status | RUO |
Descripción
2-Amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) is an enzyme involved in the tryptophan catabolic pathway, specifically in the kynurenine pathway. This pathway degrades tryptophan into several bioactive metabolites, some of which are precursors for NAD+ biosynthesis. ACMSD catalyzes the conversion of 2-amino-3-carboxymuconate-6-semialdehyde (ACMS) to 2-aminomuconate-6-semialdehyde (AMS), a step that diverts the pathway away from the production of quinolinic acid, a neuroactive compound. By regulating the flux of metabolites in the kynurenine pathway, ACMSD influences the balance between neurotoxic and neuroprotective metabolites. This enzyme is expressed in various tissues, including the brain, liver, and kidney, suggesting its importance in systemic metabolism and neuronal function. Dysregulation of ACMSD activity has been implicated in neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as psychiatric disorders like schizophrenia. Research into the molecular mechanisms and regulation of ACMSD holds promise for understanding the pathogenesis of these disorders and developing therapeutic interventions targeting the kynurenine pathway. Further investigation is needed to explore the potential of ACMSD modulation as a strategy for neuroprotection and the treatment of neurological and psychiatric conditions.
Related Products
Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Antibody
Rabbit Polyclonal against the ACMSD protein.
Ver ProductoAminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Antibody
ACMSD Antibody is a Rabbit Polyclonal against ACMSD.
Ver ProductoAminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) Antibody
ACMSD Antibody is a Rabbit Polyclonal against ACMSD.
Ver Producto